G1T38

CAS No. 1628256-23-4

G1T38 ( Lerociclib;G1T 38 )

Catalog No. M12425 CAS No. 1628256-23-4

G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 178 Get Quote
100MG Get Quote Get Quote
200MG Get Quote Get Quote
500MG Get Quote Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    G1T38
  • Note
    Research use only, not for human use.
  • Brief Description
    G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively.
  • Description
    G1T38 (Lerociclib, G1T 38) is a novel, potent and selective inhibitor of CDK4/6 with biochemical IC50 of 1 nM and 2 nM for CDK4/cyclin D1 and CDK6/cyclin D3, respectively; shows weak inhibitory effect on CDK9/cyclin T (IC50=28 nM) and CDK5/p35 (IC50=832 nM), >1,000-fold selectivity over CDK1/2/7; decreases RB1 phosphorylation, causes G1 arrest, and inhibits cell proliferation in a variety of CDK4/6-dependent tumorigenic cell lines; demonstrates equivalent or improved tumor efficacy compared to palbociclib in an ER+ breast cancer xenograft model.Breast Cancer,Phase 2 Clinical
  • Synonyms
    Lerociclib;G1T 38
  • Pathway
    Angiogenesis
  • Target
    CDK
  • Recptor
    CDK
  • Research Area
    Cancer
  • Indication
    Breast Cancer

Chemical Information

  • CAS Number
    1628256-23-4
  • Formula Weight
    474.61
  • Molecular Formula
    C26H34N8O
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    CC(C)N1CCN(CC1)C2=CN=C(C=C2)NC3=NC=C4C=C5C(=O)NCC6(N5C4=N3)CCCCC6
  • Chemical Name
    2'-((5-(4-isopropylpiperazin-1-yl)pyridin-2-yl)amino)-7',8'-dihydro-6'H-spiro[cyclohexane-1,9'-pyrazino[1',2':1,5]pyrrolo[2,3-d]pyrimidin]-6'-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Bisi JE, et al. Oncotarget. 2017 Jun 27;8(26):42343-42358.
2. Stice JP, et al. Mol Cancer Res. 2017 Jun;15(6):660-669.
molnova catalog
related products
  • CYC065

    CYC065 is a derivative of seliciclib and second generation CDK inhibitor that is mainly active on CDK2/5/9.

  • THZ-1 hydrochloride

    THZ-1 hydrochloride is a potent, selective, covalent CDK7 inhibitor with IC50 of 3.2 nM; also weakly inhibits CDK12 with IC50 of 250 nM.

  • BAY 1251152

    BAY 1251152 is the first potent, selective, orally available PTEFb/CDK9 inhibitor with biochemical IC50 of 9 nM and MOLM13 cell IC50 of 29 nM.